Iovance Raises 2026 Revenue Guidance Above Street as Amtagvi Demand Holds Up
Iovance lifts 2026 revenue guidance to $410–$420 million on strong Amtagvi demand, beating most Street estimates.
/ 2 items
Iovance lifts 2026 revenue guidance to $410–$420 million on strong Amtagvi demand, beating most Street estimates.
Iovance Biotherapeutics shares soared after reporting a 50% response rate in the first TIL therapy trial for hard-to-treat soft tissue sarcomas and solid Q4/FY2025 results with 30% revenue growth.